20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Long Road Ahead for Jak Program
Analyst Brian Skorney sees increased interest in inflammatory bowel disorder programs. Even with an aggressive timeline for Theravance's lead drug candidate for ulcerative colitis, the analyst expects a launch only by 2023, well after Pfizer Inc. (NYSE: PFE)'s Xeljanz, Celgene Corporation (NASDAQ: CELG)'s ozanimod, Gilead Sciences, Inc. (NASDAQ: GILD)'s filgotinib and AbbVie Inc (NYSE: ABBV)'s ABT-494.
Related Link: Celgene, Agios Report Collaborations with Abbott for Diagnostic Identification of IDH Mutations in AML
Attrition Post Mid-Stage Worrisome
Baird noted that some of Theravance's treatment candidates, namely Velusetrag, TD-1792 and axelopran, have all been stuck in a limbo after getting into mid-stage trials. The firm cautioned that the current valuation of the company implies a higher probability of success for the company's current pipeline than is reasonable for anyone in the sector.
At the time of writing, shares of Theravance was down 12.42 percent at $32.79.
Full ratings data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!